US2015150917A1PendingUtilityA1

Selection and Use of Lactic Acid Bacteria Preventing Bone Loss in Mammals

56
Assignee: BIOGAIA ABPriority: Jun 4, 2012Filed: Jun 4, 2013Published: Jun 4, 2015
Est. expiryJun 4, 2032(~5.9 yrs left)· nominal 20-yr term from priority
Inventors:Eamonn ConnollyRobert Allen BrittonLaura Rae Mccabe
A61P 19/10A61P 19/08A61P 19/00A61K 31/59C12Q 2600/156A61K 35/747A23L 33/135C12Q 1/689A61K 2035/11A23V 2002/00C12N 1/20C12Q 2600/16C12R 2001/225
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.

Claims

exact text as granted — not AI-modified
1 . A method for selecting a lactic acid bacterial strain for use in preventing or treating bone loss, comprising selecting a lactic acid bacterial strain having at least 95% identity to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1), and harboring an identical nucleotide relative to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1) in at least one of the following four positions: C in base pair 271 391, G in base pair 453 538, G in base pair 529 228, and C in base pair 599 338. 
     
     
         2 . A method for selecting a lactic acid bacterial strain for use in preventing or treating bone loss, comprising selecting a  Lactobacillus reuteri  harboring an identical nucleotide relative to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1) in at least one of the following four positions: C in base pair 271 391, G in base pair 453 538, G in base pair 529 228, and C in base pair 599 338. 
     
     
         3 . The method of  claim 1  or  2 , wherein the lactic acid bacterial strain harbors at least two of said four nucleotides. 
     
     
         4 . The method of any one of  claims 1 - 3 , wherein the lactic acid bacterial strain harbors at least three of said four nucleotides. 
     
     
         5 . The method of any one of  claims 1 - 4 , wherein the lactic acid bacterial strain harbors all four of said nucleotides. 
     
     
         6 . A method for selecting a lactic acid bacterial strain for use in preventing or treating bone loss, comprising selecting a lactic acid bacterial strain having at least 95% identity to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1), provided that the lactic acid bacterial strain does not harbor at least one mutation relative to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1), selected from the group of four mutations consisting of C to T in base pair 271 391, G to A in base pair 453 538, G to A in base pair 529 228, and C to T in base pair 599 338. 
     
     
         7 . The method of  claim 6 , wherein the lactic acid bacterial strain does not harbor at least two of said four mutations. 
     
     
         8 . The method of  claim 6  or  7 , wherein the lactic acid bacterial strain does not harbor at least three of said four mutations. 
     
     
         9 . The method of any one of  claims 6 - 8 , wherein the lactic acid bacterial strain does not harbor anyone of said four mutations. 
     
     
         10 . A lactic acid bacterial strain selected according to the method of any one of  claims 1 - 9  for use in the prevention or treatment of bone loss. 
     
     
         11 . A lactic acid bacterial strain having at least 95% identity to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1), and harboring an identical nucleotide relative to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1) in at least one of the following four positions: C in base pair 271 391, G in base pair 453 538, G in base pair 529 228, and C in base pair 599 338 for use in the prevention or treatment of bone loss. 
     
     
         12 . The lactic acid bacterial strain of  claim 11 , which is  L reuteri  ATCC PTA 6475. 
     
     
         13 . A composition comprising a lactic acid bacterial strain selected according to the method of any one of  claims 1 - 9 . 
     
     
         14 . A composition comprising a lactic acid bacterial strain having at least 95% identity to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1), and harboring an identical nucleotide relative to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1) in at least one of the following four positions: C in base pair 271 391, G in base pair 453 538, G in base pair 529 228, and C in base pair 599 338. 
     
     
         15 . The composition of  claim 14 , wherein the lactic acid bacterial strain is  L reuteri  ATCC PTA 6475. 
     
     
         16 . The composition of any one of  claims 13 - 15  for use in the prevention or treatment of bone loss. 
     
     
         17 . The composition of any one of  claims 13 - 15  for use in preventing bone loss in menopausal women, women who have had hysterectomy, diabetics, osteopenic individuals, osteoporotic individuals, and individuals with metabolic disturbance. 
     
     
         18 . The composition of any one of  claims 13 - 15  for use in improving bone repair after fracture. 
     
     
         19 . The composition of any one of  claims 13 - 15  in combination with vitamin D for use in preventing or treating bone loss. 
     
     
         20 . The composition of any one of  claims 13 - 15  in combination with a hormone for use in preventing or treating bone loss. 
     
     
         21 . The composition of any one of  claims 13 - 20 , which composition is a pharmaceutical composition, a food product or a food supplement. 
     
     
         22 . Use of a lactic acid bacterial strain having at least 95% identity to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1), and harboring an identical nucleotide relative to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1) in at least one of the following four positions; C in base pair 271 391, G in base pair 453 538, G in base pair 529 228, and C in base pair 599 338, for the manufacture of a pharmaceutical composition for the prevention or treatment of bone loss. 
     
     
         23 . The use of  claim 22 , wherein the lactic acid bacterial strain is  L reuteri  ATCC PTA 6475. 
     
     
         24 . A method for the treatment or prevention of bone loss, comprising administering, to an individual, a lactic acid bacterial strain having at least 95% identity to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1), and harboring an identical nucleotide relative to the genome of  L reuteri  JCM 1112 (SEQ ID NO: 1) in at least one of the following four positions: C in base pair 271 391, G in base pair 453 538, G in base pair 529 228, and C in base pair 599 338. 
     
     
         25 . The method of  claim 24 , wherein the lactic acid bacterial strain is  L reuteri  ATCC PTA 6475.

Join the waitlist — get patent alerts

Track US2015150917A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.